The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Seminar 7 – Safe drugs for neonates: the ESNEE project
Affiliation
Tartu University Hospital
Country
Estonia
1. Current status, position
- Assistant professor in the Department of Paediatrics
- Involved in pre- and postgraduate teaching and research
- Head of the Pediatric Intensive Care Unit, Tartu University Hospital
2. Education
- 1984-1990: University of Tartu, Medical Faculty, Master’s degree
- 1990-1991: Specialisation in anesthesiology and intensive care
- 1991-1999: Intensive care doctor in Pediatric Intensive Care Unit (PICU), Tartu University Hospital
- 2000 until now: Head of the PICU, Tartu University Hospital
- 2010: PhD degree, University of Tartu; the thesis focused on the efficacy and safety of antibacterial therapy in neonates at risk of early onset sepsis
- 2011 until now: Associate Professor, Department of Pediatrics, Tartu University
3. Research area
Since 1995 Dr. Metsvaht has been involved in clinical research with the neonatal sepsis as main focus of interest. She is a member of the pediatric and neonatal PK research team, Institute of Microbiology, Tartu University since 2005. Besides the neonatal sepsis, she has focused her research on the antibacterial treatment in neonates, including PK and colonization studies; drug use in neonates, including safety.
As regards her international collaboration, we can count her participation in FP7 projects Neurosis (Inhaled budesonide for the prevention of chronic lung disease in very preterm neonates – performing the clinical study) and NeoMero (The PK, safety and efficacy of meropenem in the treatment of late onset sepsis and meningitis in neonates and infants – member of the protocol writing team and PK study team); PriomedChild project ESNEE (European Study of Neonatal Excipient Exposure) – Europe-wide service evaluation study and point prevalence study of neonatal excipient exposure; participation in studies of excipient kinetics.